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Purpose: To create a digital, online atlas for organs at risk (OAR) delineation in neuro-oncology based on
high-quality computed tomography (CT) and magnetic resonance (MR) imaging.
Methods: CT and 3 Tesla (3T) MR images (slice thickness 1 mm with intravenous contrast agent) were
obtained from the same patient and subsequently fused. In addition, a 7T MR without intravenous con-
trast agent was obtained from a healthy volunteer. Based on discussion between experienced radiation
oncologists, the clinically relevant organs at risk (OARs) to be included in the atlas for neuro-oncology
were determined, excluding typical head and neck OARs previously published. The draft atlas was delin-
eated by a senior radiation oncologist, 2 residents in radiation oncology, and a senior neuro-radiologist
incorporating relevant available literature. The proposed atlas was then critically reviewed and discussed
by European radiation oncologists until consensus was reached.
Results: The online atlas includes one CT-scan at two different window settings and one MR scan (3T)
showing the OARs in axial, coronal and sagittal view. This manuscript presents the three-dimensional
descriptions of the fifteen consensus OARs for neuro-oncology. Among these is a new OAR relevant for
neuro-cognition, the posterior cerebellum (illustrated on 7T MR images).
Conclusion: In order to decrease inter- and intra-observer variability in delineating OARs relevant for
neuro-oncology and thus derive consistent dosimetric data, we propose this atlas to be used in photon
and particle therapy. The atlas is available online at www.cancerdata.org and will be updated whenever
required.
 2017 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 128 (2018) 37–43 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
38 Neuro-Oncology organs at risk atlasIn order to evaluate the added value of new radiotherapy (RT)
modalities and techniques, such as particle therapy and adaptive
highly conformal photon RT, it is essential to be able to accurately
predict the individual patient’s benefit in term of radiation-
induced side effects [1–3]. The maturation and validation of nor-
mal tissue complication probability (NTCP) models are strongly
dependent on uniform delineation of the relevant organs at risk
(OARs), and reducing the inter- and intra-observer and trial proto-
col variability between clinicians and radiotherapy departments is
an important objective. In this context, Brouwer et al. [4] and Kong
et al. [5] published atlases for OARs relevant for head and neck and
lung tumors, respectively.
During the last decade, several papers have been published on
the delineation of OARs relevant to neuro-oncology both for adults
and children [4,6,7]. These atlases may differ in minor details, but
also some major discrepancies might occur, for instance, variations
in the upper limit of the brainstem. Discrepancies in a critical OAR
may influence the dose distribution and thus compromise the cov-
erage of the target volume [4,6].
Within the Dutch Platform for Neuro-Oncology and the ESTRO
taskforce ‘‘European Particle Therapy Network (EPTN)” there was
a need to generate an atlas, which identifies the relevant OARs
for neuro-oncology and can be used both for daily practice as well
as research purposes [8]. With the ever-growing insight into the
influence of radiotherapy on neurological functions, it is essential
that this atlas can be easily updated when indicated.
Selection of OARs
In order to avoid overlap with existing head and neck atlases,
typical head and neck OARs, which were previously published,
were excluded from this consensus atlas [4]. All OARs at present
known to be relevant for radiation-induced toxicity in neuro-
oncology were included, namely: brain, brainstem, cochlea,
vestibulum & semicircular canals, cornea, lens, retina, lacrimal
gland, optic nerve, chiasm, pituitary, hippocampus and skin. In case
of paired organs, each organ separately (left and right), and the
unity of the two were contoured.
For future development of NTCP models, three distinct parts for
the brainstem were defined, and regarding cognition, the posterior
cerebellum, a new OAR possibly involved was included, as was the
separation of the hippocampus into anterior and posterior parts.
For research purposes also the hypothalamus was included. Of
note, no validated dose–response curve relationships have thus
far been published for these separate parts of the brainstem, hip-
pocampus and cerebellum.
Uniform nomenclature
To facilitate future comparison of the structures, the proposed
nomenclature is in accordance with work by Santanam et al. [9]
on standardizing naming convention in radiation oncology, illus-
trated with quotes between brackets behind every structure name,
for example: retina (‘‘Retina_R”, ‘‘Retina_L” and ‘‘Retinas”).
Delineation
The fifteen OARs introduced in several previous publications
were delineated by the first author (DE) [4,6,7]. The anterior and
posterior cerebellums were delineated by three authors (DE, LV,
IC) using the high-resolution segment of the radiation treatment
planning software (EclipseTM v11.0 software, Varian, Palo Alto,
CA). During a multi-disciplinary session, the senior radiation oncol-
ogist (DE), neuro-radiologist (AP), and two residents in radiation
oncology (LV, IC) discussed the delineation of the OARs and cameto consensus on a first draft atlas. This draft was then critically
reviewed by Dutch and international experts in neuro-oncology
and consensus on the final version of this atlas was reached.Acquisition of CT and MR
CT images were acquired with intravenous contrast (Ultravist,
150 ml of 300 mg Iodine per mL, 2 mL per sec, 5 min delay, slice
thickness 1 mm, 50 cm field of view, 120 kV, 685 mAs) using
window-width/window-level settings (WW/WL) of 120/40 and
120/1500 (SOMATOM Sensation 10, Siemens Healthcare, Erlangen,
Germany) of the head of an adult male low grade glioma patient
after first resection. Moreover, a three-dimensional spoiled gradi-
ent (3D-SPGR) axial 3T MR scan (1 mm slice thickness) of the same
patient in standard axial, sagittal and coronal reconstruction, and
an axial T2- and a gadolinium (Gadovist 1.0 mmol/ml 0.1 mL/kg
bodyweight) contrast-enhanced axial T1-weighted sequence were
acquired, with sagittal and coronal reconstruction. Both CT and MR
were obtained in the supine position with the head in a neutral
position; immobilization devices routinely used in radiation ther-
apy were used for CT acquisition. Rigid MR-CT co-registration
and delineation were performed using the EclipseTM treatment
planning system with the high-resolution segment.
For illustration purposes, 7T MR images of a healthy volunteer
were acquired (Siemens Magnetom 7T) with a slice thickness of
0.7 mm using a 32-channel head coil (Nova Medical Inc., Wilming-
ton, CA; Fig. 1). The magnetization-prepared rapid gradient-echo
(MP2RAGE) was selected for OAR delineation due to its superior
soft tissue contrast (Fig. 2). Scan parameters have previously been
published by Compter et al. [10]. Vendor-based 3D distortion cor-
rection methods were applied.Three-dimensional description of the OARs
Cornea (‘‘Cornea_R”, ‘‘Cornea_L” and ‘‘Corneas”)
The cornea is located at the anterior segment of the eyeball con-
sisting of the structures ventral to the vitreous humor, the iris, cil-
iary body, and lens [6]. Using a brush of 2–3 mm the cornea can
easily be delineated on MR as well as CT.Retina (‘‘Retina_R”, ‘‘Retina_L” and ‘‘Retinas”)
The retina is a neurosensorial membrane of 2–3 mm thickness,
located at the posterior part of the eyeball, posterior to the cornea
and lens, and is the innermost of the three layers that form the wall
of the eyeball (sclera, uvea/choroid and retina). Using a 3 mm
brush, it can be delineated on MR as well as CT as a membrane cov-
ering the posterior 5/6 of the globe, extending nearly as far as the
ciliary body. The anterior border of the retina is between the inser-
tion of the medial rectus muscle and the lateral rectus muscle, pos-
terior to the ciliary body. The optic nerve is excluded from this
contour [4,6].Lacrimal gland (‘‘LacrimalGland L”, ‘‘LacrimalGland_R” and
‘‘LacrimalGlands”)
The lacrimal gland is an almond shaped gland (18 mm cranio-
caudally, 15 mm axial length and 5 mm axial width) located in
the orbit superior-lateral to the eye, superior to the lateral rectus
muscle and lateral to the superior rectus muscle. It can be delin-
eated on CT using soft brain 120/40 or soft tissue 350/50 WW/
WL settings [4,6,11].
Fig. 1. Sagittal (midline) view of the delineation. (A) Sagittal CT image (WL 140/40), (B + C) sagittal 3 Tesla MRI (T1 with gadolinium), (D) sagittal 7 Tesla MRI. Light blue =
cerebellum anterior, dark blue = cerebellum posterior, red = midbrain, magenta = pons, pink = medulla oblongata, orange = spinal cord, light yellow = hypothalamus, green =
chiasm, purple = pituitary, orange = brainstem surface, yellow = brainstem interior.
Fig. 2. Sagittal (midline) view of cerebellum delineation on 7 Tesla MRI. From left to right: 7 Tesla MRI, sagittal, coronal and transversal. Light blue = cerebellum anterior, dark
blue = cerebellum posterior.
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The lens (diameter up to 10 mm) is a clearly visible biconvex
avascular structure, located between the vitreous humor and the
iris and can easily be delineated on CT [6]. It should be taken into
account that without instructing the patient, the position of the
lens is not fixed and can vary during treatment.Optic nerve (‘‘OpticNerve_R”, ‘‘OpticNerve_L” and ‘‘OpticNerves”)
The optic nerve (2–5 mm thick) is delineated from the posterior
edge of the eyeball, through the bony optic canal, where it narrows
slightly, to the optic chiasm. Close to the optic chiasm, an MR scan
(T1 weighted) is recommended for better delineation of the optic
nerve. Contouring the optic nerve in continuity with the chiasmis crucial for dose reporting purposes, as dose gradients can be very
steep with modern photon and proton techniques [4,12].Optic chiasm (‘‘Chiasm”)
The optic chiasm (14 mm transverse, 8 mm antero-posterior
and 2–5 mm thick) is located 1 cm superior to the pituitary gland,
which has high signal on T1 MRI, and just anterior to the pituitary
stalk (located above the sella turcica). The lateral border is the
internal carotid artery. The chiasm is superiorly located in the
antero-inferior part of the third ventricle, below the supra-optic
recess and above the infundibular recess of the third ventricle, with
the optic nerves in front and the divergence of the optic tracts
behind. The anterior cerebral arteries and the anterior communi-
cating artery are located ventral to the chiasm. A T1 weighted
40 Neuro-Oncology organs at risk atlasMR (axial, sagittal and coronal) is recommended for delineation of
the optic chiasm [4,6].Pituitary gland (‘‘Pituitary”)
The pituitary gland cannot be easily identified on axial CT,
although the bony margins of the fossa are well shown. It is
oval-shaped (craniocaudally up to 12 mm) and lies in the sella tur-
cica. Laterally, the pituitary gland is bordered by the cavernous
sinuses, which are well visible with intravenous contrast agent, it
is just inferior to the brain, and is connected to the hypothalamus
by its pituitary stalk. The borders of the pituitary gland can be
defined best in the sagittal view [4,5]. Alternatively, the inner part
of the sella turcica can be used as a surrogate anatomical bony
structure best identified using bone 1500/950 or soft tissue
350/50 WL/WW on CT.Hypothalamus (‘‘Hypothalamus_R, ‘‘Hypothalamus_L” and
‘‘Hypothalami”)
The hypothalamus (2–4 cm3) is a polygonal structure consisting
of two separate volumes on each side of the third ventricle, delin-
eated using MR-based anatomic landmarks representing surrogate
boundaries for the hypothalamus itself. The superior boundaries
are the axial slices containing the anterior and the posterior com-
missure. Inferiorly, the boundary consists of the base of the third
ventricle or the visible edge of the cerebrospinal fluid (CSF) space
within the suprasellar cistern, while posteriorly the contour
reaches to the level of the interpeduncular fossa. The mammillary
bodies should be included in the contour. The medial border con-
sists of the third ventricle or the visible CSF space. Since the lateral
border is not clearly visible, the contour was bounded laterally 3
mm from the third ventricle. Delineation on a T1 weighted MR is
strongly recommended [13–16].Hippocampus (‘‘Hippocampus_P_R”, ‘‘Hippocampus_P_L”,
‘‘Hippocampus_A_R”, ‘‘Hippocampus_A_L”, and ‘‘Hippocampi”)
The literature describes considerable age- and disease-specific
variability in hippocampal size (range 2.8–4.0 cm3) and location
[7,17–19]. The hippocampus (HC) is delineated as the gray matter
medial to the medial boundary of the temporal horn of the lateral
ventricle, bordered medially by the quadrigeminal cistern as
described by Gondi et al. [7]. Blum et al. [20] suggest a separation
of the HC into a posterior (corpus) and anterior (head) part using
the lateral ventricle as dorsal border for the anterior hippocampus.
In sagittal view, the head of the HC is separated from the body at
the narrowing of the HC, with the uncus located dorsally [20,21].
Delineation on MR (T1 weighted) is essential.Cochlea (‘‘Cochlea_R”, ‘‘Cochlea_L” and ‘‘Cochleas”)
The cochlea is a spiral structure (up to 0.6 cm3) located in a
bony cavity in the petrous portion of the temporal bone, caudal
to the semicircular canals, lateral to the internal auditory canal.
Using a WW/WL setting of 120/1500 on CT images, its volume
can be defined as a small cavity. The structures of the inner ear
are well visible on MR (T2 weighted) images [4,6]. The semicircular
canals should not be included.Vestibular and semicircular canal (‘‘VSCC_R”, ‘‘VSCC_L”, ‘‘VSCCs”)
As the semicircular canals are a part of the bony labyrinth with
the superior, posterior and lateral canals aligned in three planes,
delineation is advised using the bone setting on CT images (WW/
WL 120/1500). The semicircular canal is located laterally and cra-nially of the cochlea. The canals are also visible as small cavities
on MR (T2 weighted) [6].Brain Stem (‘‘BrainStem”, ‘‘Brainstem_surface”, ‘‘Brainstem_interior”
or ‘‘Midbrain”, ‘‘Pons” and ‘‘Medulla Oblongata”)
The brainstem is to be contoured on MR images and can be
divided into three parts, from cranial to caudal, the midbrain, pons
and medulla oblongata. The midbrain is defined from the nigral
substance at the cerebral peduncle to the upper border of the pons.
The pons is an oval shaped structure on sagittal views, which is
easy to discriminate (see Fig. 1C). The caudal limit of the medulla
oblongata is the tip of the dens of C2 (i.e., the odontoid peg), which
is also the cranial border of the spinal cord; the cranial limit is the
ponto-medullary junction [4,6,22]. For practical reason the cere-
bral aqueduct is included until it becomes the 4th ventricle. The
brainstem interior is the brainstem surface contour cropped by 2
mm (inner border). The brainstem surface is the brainstem exclud-
ing the brainstem interior [23,24]. These structures are contoured
automatically (and checked thereafter) using a built-in delineation
tool commonly found in treatment planning systems.Brain (‘‘Brain” and ‘‘Brain_Supratentorial”)
The delineation of the brain includes the cerebellum, CSF and
small brain vessels, and excludes the brainstem and large cerebel-
lar vessels, such as the sigmoid sinus, transverse sinus and superior
sagittal sinus (Fig. 3C). For delineation purposes, CT in brain soft
tissue 350/40 WW/WL-settings is recommended. Alternatively,
the brain can be contoured automatically (and checked thereafter)
using a built-in delineation tool commonly found in the majority of
treatment planning systems [4,6,25]. In the middle cranial fossa
the carotid canal and cavernous sinuses, most easily seen on
contrast-enhanced T1 MRI, should not be included. The supraten-
torial brain equals the ‘‘Brain” excluding the cerebellum
(see Section ‘‘Cerebellum (‘‘Cerebellum_P”, ‘‘Cerebellum_A’ and
‘‘Cerebellum”)”).Cerebellum (‘‘Cerebellum_P”, ‘‘Cerebellum_A’ and ‘‘Cerebellum”)
The separation of the cerebellum into an anterior and posterior
part is best seen on the sagittal T1 weighted MR (see Fig. 1). The
anterior cerebellum consists of the cranial part of the cerebellum
including half of the medullary corpus. The posterior cerebellum
consists of the caudal and posterior part of the cerebellum with a
cranial border including the lower half of the medullary corpus.
This part includes the flocculonodular lobe. The primary fissure,
which is best seen on 7-Tesla MR (see Fig. 2), divides the anterior
part from the posterior part of the cerebellum [26]. The lateral bor-
ders for both parts are the large vessels (the sigmoid sinus, trans-
verse sinus and superior sagittal sinus) and CSF, which are both
excluded.Skin (‘‘Skin”)
The skin is the volume defined by the body contour (outer bor-
der) and the body contour cropped by 5 mm (inner border), both
created on the CT. This structure is contoured automatically (and
checked thereafter) using a built-in delineation tool commonly
found in treatment planning systems [4,6,25].
All mentioned OARs are delineated on CT and MR (see Fig. 3) in
an easily accessible delineation atlas at www.cancerdata.org [27].
Fig. 3. 3D view of the OARs delineation on CT. (A) From ventral to dorsal: yellow = cornea, orange = retina, brown = lacrimal gland, green = optic nerve, light green = chiasm,
purple = pituitary, yellow (central) = hypothalamus, red = midbrain, green (central) = hippocampus anterior, dark green = hippocampus posterior, pink = cochlea, magenta =
pons, pink = medulla oblongata, orange = spinal cord, light blue = cerebellum anterior, dark blue = cerebellum posterior. (B) From cranial to caudal: yellow = hypothalamus,
red = midbrain, light green = chiasm, green = hippocampus anterior, dark green = hippocampus posterior, magenta = pons, pink = medulla oblongata, Light blue =
anterior cerebellum, dark blue = posterior cerebellum, orange = spinal cord. (C) Yellow = brain, red = brainstem, orange = spinal cord.
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The presented atlas for contouring OARs involved in neuro-
oncology aims at reducing the inter- and intra-observer delin-
eation variability and thus enabling more consistent plan compar-
ison. This is especially relevant when comparing different radiation
treatment techniques and modalities, and for establishing detailed
dose–response relationships and NTCP models for different OARs.
Toxicity to the optical system is a feared complication especially
when it results in partial or total loss of vision or pain to the eye.
Despite their small volume, a separate delineation of the different
optical structures is crucial in order to derive dose–volume his-
tograms and predict post-radiation toxicity. The optic chiasm is
an anatomically cross-shaped structure, as is depicted by Scoc-
cianti et al. [6] and not round as presented in the atlas by Brouwer
et al. [4]. Moreover, the chiasm should be contoured in continuity
with both optic nerves in order to prevent high-dose deposits in
un-delineated voxels. The retina is to be delineated separately from
the vitreous body, since radiation induced retinopathy can be trea-
ted if observed in an early state. Consequently, correct dose calcu-
lation is of utmost relevance in order to refer a patient suffering
from this radiation induced side-effect [28]. Separate delineation
of the cornea is proposed since toxicity and tolerance dose differ
from that of the retina [4,28,29]. Damage to the cornea, radiation
keratitis, is painful and deteriorates sight. The mean radiation dose
to the lacrimal gland is related to the development of a dry eye,
which can be painful and render the eye susceptible to infections
[28]. A cataract can develop at a rather low dose to the lens. This
side-effect can be alleviated by surgical implantation of an artificial
lens [28]. A normal lens is well seen because of its high protein
content, whereas an artificial lens is difficult to see on CT or MR,
but since it tolerates radiation dose, delineation is not required.
Hypo-pituitarismmay take a long time to be diagnosed since its
symptoms can be vague. Depending on the mean dose to the pitu-
itary gland, an early referral to an endocrinologist can facilitate
early initiation of treatment and thus prevent impaired quality of
life [30,31]. In general, it is advised to delineate the entire sella
content to be sure the whole pituitary is included rather than the
central part only, excluding the suprasellar part of the infundibu-
lum [4,6]. Even though there are no established dose constraintsfor the hypothalamus available yet, we believe that these data
need to be collected in a prospective manner, in order to correlate
levels of hormone production and regulation of metabolic pro-
cesses with delivered radiation dose.
Hearing preservation after radiotherapy is known to be related
to dose to the cochlea [32–34]. There is agreement in the literature
on its delineation, most optimally done on a CT scan with thin
slices using a bone WW/WL-setting considering its location in
the mastoid bone [4,6]. Since dizziness is a side-effect occasionally
reported after radiotherapy it was decided to delineate the semicir-
cular canals as well, using the same WW/WL-settings as for the
cochlea, although future data are needed to establish a validated
dose constraint.
Recent literature has shown some dose–response relationship
between the hippocampus and cognition as described by Gondi
et al. [34] using the absolute radiation dose to 40% of both hip-
pocampi (D40%). We firmly encourage delineating the hippocampi
separately and into anterior and posterior parts, since the left hip-
pocampus is known to be dominant in most patients (including
left-handed patients) for verbal memory, and the right hippocam-
pus for non-verbal memory also known as visual memory. More-
over, the posterior parts of the hippocampi are more related to
memory than the anterior parts [35–39].
The brain is often automatically delineated and for practical
reasons the included small vessels are left in the contour since
editing the contour would be too time consuming. There are dose
constraints for brain tissue, especially on high doses related to
temporal lobe radionecrosis in head and neck cancer patients
[40–45]. Regarding neuro-cognition, some publications on pedi-
atric patients have shown a correlation between low dose radiation
to the supra-tentorial brain and cognitive decline [40,46]. Further
data are needed to transfer this knowledge to adult patients. Data
on whole brain radiotherapy and prophylactic cranial irradiation
have hinted at the negative effect of low dose on cognition [47–
54]. However, there still is a strong need for an adult NTCP model
on brain tissue and cognition.
Symptomatic brainstem necrosis is a feared, but rare complica-
tion following radiotherapy to the brain [55,56]. It was decided to
contour the brainstem in three anatomically distinct parts, because
some hypothesize that specific volumes within the brainstem are
42 Neuro-Oncology organs at risk atlasmore sensitive to radiation than others. In particle beam therapy,
the anterior surface and center of the brainstem are delineated
separately since a higher tolerance at the surface of the brainstem
has been observed [23,24]. This should be subject to further
research for both photon and particle radiotherapy.
The delineation of the cerebellum is also added as a possible
new OAR for research purposes, since there are data suggesting a
relationship between the posterior cerebellum and cognition
[57]. Cantelmi et al. [58] state that recognition of the important
cognitive contributions of the cerebellum might lead to improved
cognitive outcome and quality of life. This definitely needs further
research into a possible dose–response relationship and tolerance
dose, which is only possible when agreement is reached in the
delineation, as proposed based on Schmahmann et al. [26,55,58].
For radiation treatment planning purposes, the skin is added as
an OAR since alopecia and erythema are disturbing side-effects.
Using the skin structure enables lowering the dose during treat-
ment planning, which is of particular importance in proton therapy
with its relatively high entry dose [59].
A limitation of the atlas is the fact that the three dimensional
angulation possibilities in a radiation treatment planning systems
are often limited and patients are mostly not aligned perfectly in
the midline. This is why the atlas was based on a random CT/
MR-dataset of an imperfectly aligned patient, resembling routine
clinical practice. The atlas includes transversal, coronal and sagittal
views to assist the delineation process. A second potential limita-
tion of this atlas is that we had to limit the number of OARs pro-
posed for otherwise the atlas would have been impracticable and
thus not used in routine clinical practice. Future research should
unravel the role of additional OARs and the NTCP value for: Eus-
tachian tube, circle of Willis, optic tract, frontal & temporal lobe,
anterior eye chambers, macula, mammillary bodies, spinal canal
and cerebrospinal space. Thirdly, this atlas does not summarize
the available literature on dose constraints for the contoured
organs at risk; this enormous effort will be a separate project of
the EPTN. Finally, even though this atlas was contoured on a 3T
MR scan, it can be easily transferred to 1.5T MR images.
Uniform contouring of structures in the central nervous system,
both in photon and particle therapy, is considered important for:
(1) the generalization of normal tissue dose constraints, (2) estab-
lishment or update of NTCP models taking into account new radi-
ation treatment techniques, and (3) for comparative multicenter
clinical studies on radiotherapy in patients with primary brain
tumors. Besides uniform contouring, consensus on OAR dose con-
straints is also required for implementing and improving NTCP
models. A separate article on dose constraints for the given OARs,
again consented by the EPTN, is currently being prepared.Conclusion
In order to decrease variability in delineating OARs involved in
neuro-oncology and to allow the generation of consistent dosimet-
ric data, we propose an atlas for neuro-oncology including some
new OARs in order to give an anatomical basis for the development
of international acknowledged constraints and volumes. This will
enable the community to amplify existing and new NTCP models
such that more accurate prediction, and possibly prevention, of
long-term radiation toxicity comes within reach. The atlas is avail-
able online on www.cancerdata.org and will be updated whenever
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